{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:53:02Z","timestamp":1793321582154,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["CA191075"],"award-info":[{"award-number":["CA191075"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["T\\u00DCB\\u0130TAK-2219 \/ 1059B192101179"],"award-info":[{"award-number":["T\\u00DCB\\u0130TAK-2219 \/ 1059B192101179"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS113822"],"award-info":[{"award-number":["R01 NS113822"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejps.2025.107255","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:34:04Z","timestamp":1757000044000},"page":"107255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy"],"prefix":"10.1016","volume":"213","author":[{"given":"Eren","family":"Aytekin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semer","family":"Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakhos A.","family":"Tannous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-2772","authenticated-orcid":false,"given":"Sibel Bozda\u011f","family":"Pehlivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-5975","authenticated-orcid":false,"given":"Christian E.","family":"Badr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107255_bib0001","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","article-title":"Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma","volume":"17","author":"Berghoff","year":"2015","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ejps.2025.107255_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/10717540600739914","article-title":"Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies","volume":"14","author":"Bond\u00ec","year":"2007","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2025.107255_bib0003","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/cancers14133161","article-title":"Survival outcomes and prognostic factors in glioblastoma","volume":"14","author":"Brown","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2025.107255_bib0004","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-020-03481-0","article-title":"Combination immunotherapy strategies for glioblastoma","volume":"151","author":"Chan","year":"2021","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejps.2025.107255_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2025.107255_bib0006","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.bbrc.2018.05.064","article-title":"Temozolomide combined with PD-1 Antibody therapy for mouse orthotopic glioma model","volume":"501","author":"Dai","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2025.107255_bib0007","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jphp.12644","article-title":"Alpha-lipoic acid\u2013stearylamine conjugate-based solid lipid nanoparticles for tamoxifen delivery: formulation, optimization, in-vivo pharmacokinetic and hepatotoxicity study","volume":"68","author":"Dhaundiyal","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107255_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121682","article-title":"Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression","volume":"618","author":"Di Filippo","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107255_bib0009","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2478\/acph-2019-0054","article-title":"In vitro evaluation of stearylamine cationic nanoemulsions for improved ocular drug delivery","volume":"69","author":"Dukovski","year":"2019","journal-title":"Acta Pharmaceutica"},{"key":"10.1016\/j.ejps.2025.107255_bib0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3390\/pharmaceutics12050451","article-title":"Nanostructured lipid carriers to mediate brain delivery of temazepam: design and in vivo study","volume":"12","author":"Eleraky","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107255_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13321-019-0383-2","article-title":"SAR and QSAR modeling of a large collection of LD 50 rat acute oral toxicity data","volume":"11","author":"Gadaleta","year":"2019","journal-title":"J. Cheminform."},{"key":"10.1016\/j.ejps.2025.107255_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43094-022-00414-8","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107255_bib0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jps.22271","article-title":"Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen","volume":"100","author":"Gonz\u00e1lez-Mira","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2025.107255_bib0014","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107255_bib0015","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.3390\/molecules27041170","article-title":"Effect of cationic lipid nanoparticle loaded siRNA with stearylamine against chikungunya virus","volume":"27","author":"Jeengar","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.ejps.2025.107255_bib0016","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/pharmaceutics12090860","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme","volume":"12","author":"Jnaidi","year":"2020","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107255_bib0017","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/neuonc\/noz015","article-title":"Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition","volume":"21","author":"Karachi","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ejps.2025.107255_bib0018","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.2147\/IJN.S310464","article-title":"Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid\u2011Coated Superparamagnetic Iron Oxide","author":"Lee","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejps.2025.107255_bib0019","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00280-020-04048-6","article-title":"Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation","volume":"85","author":"Li","year":"2020","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.ejps.2025.107255_bib0020","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 axis in glioblastoma multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107255_bib0021","doi-asserted-by":"crossref","first-page":"293","DOI":"10.14233\/ajchem.2018.20902","article-title":"Development of solid lipid nanoparticles of Gac (Momordica cocochinensis Spreng) oil by nano-emulsion technique","volume":"30","author":"Mai","year":"2018","journal-title":"Asian J. Chem"},{"key":"10.1016\/j.ejps.2025.107255_bib0022","first-page":"1","article-title":"Arming AAV9 with a Single-Chain Fragment Variable Antibody Against PD-1 for Systemic Glioblastoma Therapy","author":"Maksoud","year":"2024","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2025.107255_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114238","article-title":"Development of cationic solid lipid nanoparticles incorporating cholesteryl-9-carboxynonanoate (9CCN) for delivery of antagomiRs to macrophages","volume":"197","author":"Mall\u00e9n","year":"2024","journal-title":"Eur. J. Pharmaceut. Biopharmaceut."},{"key":"10.1016\/j.ejps.2025.107255_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2018.03.002","article-title":"Insights into maleimide-thiol conjugation chemistry: conditions for efficient surface functionalization of nanoparticles for receptor targeting","volume":"282","author":"Mart\u00ednez-Jothar","year":"2018","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.ejps.2025.107255_bib0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3390\/pharmaceutics16070863","article-title":"Development of a Versatile Nanostructured Lipid Carrier (NLC) Using Design of Experiments (DoE)\u2014Part II: incorporation and Stability of Butamben with Different Surfactants","volume":"16","author":"Matarazzo","year":"2024","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107255_bib0026","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/pharmaceutics13040437","article-title":"Evaluation and comparison of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) as vectors to develop hydrochlorothiazide effective and safe pediatric oral liquid formulations","volume":"13","author":"Mura","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2025.107255_bib0027","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1080\/02652048.2023.2264386","article-title":"Design and evaluations of a nanostructured lipid carrier loaded with dopamine hydrochloride for intranasal bypass drug delivery in Parkinson\u2019s disease","volume":"40","author":"Neha","year":"2023","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2025.107255_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1525243","article-title":"Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma","volume":"8","author":"Park","year":"2019","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.ejps.2025.107255_bib0029","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1080\/10717544.2016.1189465","article-title":"Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?","volume":"23","author":"Qu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2025.107255_bib0030","doi-asserted-by":"crossref","first-page":"16824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.ejps.2025.107255_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67411-w","article-title":"GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models","volume":"10","author":"Sanchez","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2025.107255_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108807","article-title":"Glioblastoma extracellular vesicles modulate immune PD-L1 expression in accessory macrophages upon radiotherapy","volume":"27","author":"Schweiger","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ejps.2025.107255_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002181","article-title":"Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma","volume":"9","author":"Simonds","year":"2021","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.ejps.2025.107255_bib0034","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3109\/10717544.2015.1064186","article-title":"Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy","volume":"23","author":"Song","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2025.107255_bib0035","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.3390\/cancers13174485","article-title":"In vitro and in vivo enhancement of temozolomide effect in human glioblastoma by non-invasive application of cold atmospheric plasma","volume":"13","author":"Soni","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2025.107255_bib0036","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijpharm.2018.04.001","article-title":"Effects of cationic liposomes with stearylamine against virus infection","volume":"543","author":"Tahara","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107255_bib0037","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/molecules25030685","article-title":"Sucupira oil-loaded nanostructured lipid carriers (NLC): lipid screening, factorial design, release profile, and cytotoxicity","volume":"25","author":"Vieira","year":"2020","journal-title":"Molecules."},{"key":"10.1016\/j.ejps.2025.107255_bib0038","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.3390\/ijms22073453","article-title":"Successful partnerships: exploring the potential of immunogenic signals triggered by TMZ, CX-4945, and combined treatment in Gl261 glioblastoma cells","volume":"22","author":"Villama\u00f1an","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107255_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.119848","article-title":"UV spectroscopic method for estimation of temozolomide: application in stability studies in simulated plasma pH, degradation rate kinetics, formulation design, and selection of dissolution media","volume":"258","author":"Waghule","year":"2021","journal-title":"Spectrochimica Acta Part A: Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejps.2025.107255_bib0040","first-page":"1161","article-title":"Temozolomide promotes immune escape of GBM cells via upregulating PD-L1","volume":"9","author":"Wang","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107255_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12672-023-00633-2","article-title":"Markedly divergent effects of Ouabain on a Temozolomide-resistant (T98G) vs. a Temozolomide-sensitive (LN229) Glioblastoma cell line","volume":"14","author":"Weidemann","year":"2023","journal-title":"Discover Oncol."},{"key":"10.1016\/j.ejps.2025.107255_bib0042","doi-asserted-by":"crossref","first-page":"8775","DOI":"10.3390\/ijms21228775","article-title":"Anti-pd-1 immunotherapy in preclinical gl261 glioblastoma: influence of therapeutic parameters and non-invasive response biomarker assessment with mrsi-based approaches","volume":"21","author":"Wu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107255_bib0043","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijpharm.2007.07.012","article-title":"Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells","volume":"348","author":"Yuan","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2025.107255_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417628","article-title":"Correlation of MR-Based Metabolomics and Molecular Profiling in the Tumor Microenvironment of Temozolomide-Treated Orthotopic GL261 Glioblastoma in Mice","volume":"24","author":"Zhao","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725002532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725002532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:27:46Z","timestamp":1757770066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725002532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"alternative-id":["S0928098725002532"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107255","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-action nanotherapy: Temozolomide-loaded, anti-PD-L1 scFv-functionalized lipid nanocarriers for targeted glioblastoma therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107255","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107255"}}